CN118436556A - A resveratrol supramolecule and its preparation method and application in the preparation of cosmetics - Google Patents
A resveratrol supramolecule and its preparation method and application in the preparation of cosmetics Download PDFInfo
- Publication number
- CN118436556A CN118436556A CN202410555518.5A CN202410555518A CN118436556A CN 118436556 A CN118436556 A CN 118436556A CN 202410555518 A CN202410555518 A CN 202410555518A CN 118436556 A CN118436556 A CN 118436556A
- Authority
- CN
- China
- Prior art keywords
- resveratrol
- polygonum cuspidatum
- supramolecule
- extract
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 title claims abstract description 121
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 title claims abstract description 121
- 235000021283 resveratrol Nutrition 0.000 title claims abstract description 121
- 229940016667 resveratrol Drugs 0.000 title claims abstract description 121
- 239000002537 cosmetic Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 21
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 141
- 239000000203 mixture Substances 0.000 claims abstract description 71
- 239000002904 solvent Substances 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 33
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011259 mixed solution Substances 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 3
- 241001648835 Polygonum cuspidatum Species 0.000 claims abstract 9
- 230000000694 effects Effects 0.000 claims description 21
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- -1 hydroxypropyl α-cyclodextrin Chemical compound 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 4
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 4
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 claims description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 2
- 230000003255 anti-acne Effects 0.000 claims description 2
- 230000003064 anti-oxidating effect Effects 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
- 230000002087 whitening effect Effects 0.000 claims description 2
- 229940055019 propionibacterium acne Drugs 0.000 abstract description 30
- 238000002156 mixing Methods 0.000 abstract description 24
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 206010040880 Skin irritation Diseases 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000036556 skin irritation Effects 0.000 abstract description 3
- 231100000475 skin irritation Toxicity 0.000 abstract description 3
- 238000001694 spray drying Methods 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 description 132
- 238000010828 elution Methods 0.000 description 78
- 239000011347 resin Substances 0.000 description 72
- 229920005989 resin Polymers 0.000 description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 36
- 239000000741 silica gel Substances 0.000 description 36
- 229910002027 silica gel Inorganic materials 0.000 description 36
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- 239000007864 aqueous solution Substances 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 239000003642 reactive oxygen metabolite Substances 0.000 description 17
- 241000186427 Cutibacterium acnes Species 0.000 description 14
- 241000252212 Danio rerio Species 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 239000012535 impurity Substances 0.000 description 12
- 239000012046 mixed solvent Substances 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 210000002257 embryonic structure Anatomy 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 230000007794 irritation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000020827 calorie restriction Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 241001248531 Euchloe <genus> Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000489523 Veratrum Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical group C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940057613 veratrum Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 108700024526 zebrafish sox32 Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Oncology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及生物医药技术领域,具体公开了一种白藜芦醇超分子的制备方法,其包含如下步骤:S11.取环糊精衍生物溶解在溶剂中,接着加入白藜芦醇,在40~80℃下搅拌1~3h得混合液;S12.将混合液进行喷雾干燥后即得所述的白藜芦醇超分子。研究表明,通过本发明所述方法制备得到的白藜芦醇超分子,其相比于等量的白藜芦醇,具有更好的抗氧化作用;此外,相比于白藜芦醇还可以降低对皮肤的刺激。进一步研究表明,将白藜芦醇超分子和虎杖根提取物混合后得到的组合物,其还具有显著甚者优异的抗痤疮丙酸杆菌。因此,将本发明所述的白藜芦醇超分子和/或组合物作为活性成分用于制备化妆品或药物具有重要的应用价值。
The present invention relates to the field of biomedical technology, and specifically discloses a method for preparing a resveratrol supramolecule, which comprises the following steps: S11. dissolving a cyclodextrin derivative in a solvent, then adding resveratrol, and stirring at 40-80°C for 1-3h to obtain a mixed solution; S12. spray drying the mixed solution to obtain the resveratrol supramolecule. Studies have shown that the resveratrol supramolecule prepared by the method of the present invention has a better antioxidant effect than an equal amount of resveratrol; in addition, compared with resveratrol, it can also reduce skin irritation. Further studies have shown that the composition obtained by mixing the resveratrol supramolecule and the root extract of Polygonum cuspidatum also has significant or even excellent anti-Propionibacterium acnes. Therefore, the resveratrol supramolecule and/or the composition of the present invention as an active ingredient for preparing cosmetics or drugs has important application value.
Description
技术领域Technical Field
本发明涉及生物技术领域,具体涉及一种白藜芦醇超分子及其制备方法与在制备化妆品中的应用。The invention relates to the field of biotechnology, and in particular to a resveratrol supramolecule and a preparation method thereof and application thereof in the preparation of cosmetics.
背景技术Background technique
爱美之心人皆有之,健康年轻的皮肤是所有人的追求,抗皱紧致等抗衰老功效产品在化妆品市场占据重要地位,在化妆品各功效产品中市场占有率排名第一。因紫外线暴露导致皮肤里活性氧自由基(ROS)过多,ROS过多会导致皮肤胶原蛋白流失,成纤细胞减少,皮肤失去弹性、皱纹增多,即所谓的皮肤光老化。化妆品里添加适当的抗氧化剂可以帮助人体清除多余的ROS,寻找高效安全且能非常方便的在化妆品配方里使用的抗氧化剂是对抗光老化的重要手段。Everyone loves beauty, and healthy and youthful skin is what everyone pursues. Anti-aging products such as anti-wrinkle and firming products occupy an important position in the cosmetics market, and rank first in market share among various cosmetic products. Ultraviolet exposure causes excessive reactive oxygen free radicals (ROS) in the skin, which can lead to the loss of skin collagen, a decrease in fibroblasts, loss of skin elasticity, and increased wrinkles, which is the so-called skin photoaging. Adding appropriate antioxidants to cosmetics can help the body remove excess ROS. Finding antioxidants that are efficient, safe, and very convenient to use in cosmetic formulas is an important means to combat photoaging.
白藜芦醇是一种非黄酮类多酚化合物,其化学名称为3,4',5-三羟基-1,2-二苯基乙烯,主要来源于葡萄、虎杖、花生、藜芦、桑葚等植物。2003年哈佛大学教授DavidSinclair及其团队研究发现白藜芦醇可激活乙酰化酶,增加酵母菌的寿命;Howitz等发现白藜芦醇可以作为最强的沉默信息因子(silent information regulation 2homolog1,SIRT1)的激活剂,可模拟热量限制(calorie restriction,CR)抗衰老反应,参与有机生物平均生命期的调控。CR是SIRT1的强诱导剂,能增加SIRT1在脑、心、肠、肾、肌肉和脂肪等器官组织中的表达,CR能够引起延缓衰老和延长寿命的生理变化,最显著的可延长50%。研究还发现白藜芦醇对鼠肝细胞癌、乳腺癌、结肠癌、胃癌、白血病等多种肿瘤细胞均有显著抑制作用,同时还具有抗菌、抗氧化、免疫调节、抗喘等一些其他生物活性,白藜芦醇已经广泛应用于食品、保健品领域,近年来也作为抗氧化剂应用在化妆品领域。白藜芦醇虽然有很强的抗氧化活性,但由于在水中难溶、有一定的刺激性等缺陷限制了其在化妆品的广泛应用。因此,白藜芦醇为原料,开发出更多的药物或化妆品用活性成分,具有重要的应用价值。Resveratrol is a non-flavonoid polyphenol compound, with the chemical name of 3,4',5-trihydroxy-1,2-diphenylethylene, mainly derived from plants such as grapes, knotweed, peanuts, Veratrum, and mulberries. In 2003, Harvard University professor David Sinclair and his team found that resveratrol can activate acetylase and increase the life span of yeast; Howitz et al. found that resveratrol can be used as the strongest activator of silent information regulation 2homolog1 (SIRT1), which can simulate the anti-aging response of calorie restriction (CR) and participate in the regulation of the average life span of organic organisms. CR is a strong inducer of SIRT1, which can increase the expression of SIRT1 in organs and tissues such as brain, heart, intestine, kidney, muscle and fat. CR can cause physiological changes that delay aging and prolong life, the most significant of which can prolong life by 50%. Studies have also found that resveratrol has a significant inhibitory effect on various tumor cells such as rat hepatocellular carcinoma, breast cancer, colon cancer, gastric cancer, leukemia, etc. It also has some other biological activities such as antibacterial, antioxidant, immunomodulatory, and anti-asthmatic. Resveratrol has been widely used in the fields of food and health products. In recent years, it has also been used as an antioxidant in the field of cosmetics. Although resveratrol has strong antioxidant activity, its wide application in cosmetics is limited by its defects such as poor solubility in water and certain irritation. Therefore, using resveratrol as a raw material to develop more active ingredients for drugs or cosmetics has important application value.
超分子概念是1987年诺贝尔化学奖获得者莱恩提出,超分子是指两个或多个分子以非共价键的方式结合在一起组成的复合分子,目前已经在医药、食品、环境、材料等领域获得广泛应用,近年来也被引入化妆品领域。由多个葡萄糖单元组成的环糊精及其衍生物的环状内空腔可与客体分子通过主客体相互作用发生自组装得到超分子,是一类在超分子领域广泛应用的主体。环糊精及其衍生物的内腔在0.47-0.75nm之间,可以作为一个分子胶囊,分子胶囊的内腔疏水外壳亲水,可以很好的将水中溶解性不好的分子装入,既可以保护客体分子不被氧化变色也可有效增加其水溶性,而且可以起到缓释、促进皮肤渗透增大生物利用度、降低客体分子刺激性的作用。然而,现有技术并未有关于白藜芦醇与环糊精衍生物形成超分子的研究报道。The concept of supramolecules was proposed by Ryan, the winner of the 1987 Nobel Prize in Chemistry. Supramolecules refer to complex molecules composed of two or more molecules bound together in a non-covalent bond. They have been widely used in the fields of medicine, food, environment, materials, etc., and have also been introduced into the field of cosmetics in recent years. The annular inner cavity of cyclodextrin and its derivatives composed of multiple glucose units can self-assemble with guest molecules through host-guest interactions to obtain supramolecules, which is a class of subjects widely used in the field of supramolecules. The inner cavity of cyclodextrin and its derivatives is between 0.47-0.75nm, which can be used as a molecular capsule. The inner cavity of the molecular capsule is hydrophobic and the outer shell is hydrophilic, which can well load molecules with poor solubility in water, protect the guest molecules from oxidation and discoloration, and effectively increase their water solubility. It can also play a role in sustained release, promote skin penetration, increase bioavailability, and reduce the irritation of guest molecules. However, there is no research report on the formation of supramolecules by resveratrol and cyclodextrin derivatives in the prior art.
发明内容Summary of the invention
为了克服现有技术中存在的至少之一的技术问题,本发明提供了一种白藜芦醇超分子及其制备方法与在制备化妆品中的应用。In order to overcome at least one of the technical problems existing in the prior art, the present invention provides a resveratrol supramolecule and a preparation method thereof and an application thereof in the preparation of cosmetics.
本发明首先提供了一种白藜芦醇超分子的制备方法,其包含如下步骤:The present invention first provides a method for preparing resveratrol supramolecules, which comprises the following steps:
S11.取环糊精衍生物溶解在溶剂中,接着加入白藜芦醇,在40~80℃下搅拌1~3h得混合液;S11. dissolving a cyclodextrin derivative in a solvent, then adding resveratrol, and stirring at 40 to 80° C. for 1 to 3 hours to obtain a mixed solution;
S12.将混合液进行喷雾干燥后即得所述的白藜芦醇超分子。S12. The mixed solution is spray-dried to obtain the resveratrol supramolecule.
本发明提供了一种全新方法制备得到的白藜芦醇超分子;研究表明,通过本发明所述方法制备得到的白藜芦醇超分子,其相比于等量的白藜芦醇,具有更好的抗氧化作用;此外,相比于白藜芦醇还可以降低对皮肤的刺激。The present invention provides a resveratrol supramolecule prepared by a completely new method; studies have shown that the resveratrol supramolecule prepared by the method of the present invention has a better antioxidant effect than an equal amount of resveratrol; in addition, compared with resveratrol, it can also reduce skin irritation.
优选地,步骤S11中,环糊精衍生物与白藜芦醇以及溶剂的重量比为70~99:1~30:200~400。Preferably, in step S11, the weight ratio of the cyclodextrin derivative to resveratrol and the solvent is 70-99:1-30:200-400.
最优选地,步骤S11中,环糊精衍生物与白藜芦醇以及溶剂的重量比为90:10:270。Most preferably, in step S11, the weight ratio of the cyclodextrin derivative to resveratrol and the solvent is 90:10:270.
优选地,步骤S11中的环糊精衍生物选自α-环糊精、β-环糊精、γ-环糊精、羟丙基α-环糊精、羟丙基β-环糊精、羟丙基γ-环糊精中的一种或几种。Preferably, the cyclodextrin derivative in step S11 is selected from one or more of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxypropyl α-cyclodextrin, hydroxypropyl β-cyclodextrin and hydroxypropyl γ-cyclodextrin.
本发明还提供了一种由上述制备方法制备得到的白藜芦醇超分子。The present invention also provides a resveratrol supramolecule prepared by the above preparation method.
本发明还提供了一种组合物,其包含上述白藜芦醇超分子。The present invention also provides a composition comprising the above-mentioned resveratrol supramolecule.
优选地,所述的组合物,包含上述白藜芦醇超分子以及虎杖根提取物。Preferably, the composition comprises the above-mentioned resveratrol supramolecule and Polygonum cuspidatum root extract.
发明人在研究中进一步发现,将白藜芦醇超分子和虎杖根提取物混合后得到的组合物,其对痤疮丙酸杆菌具有抗菌效果。由于痤疮丙酸杆菌是引起痤疮和痘痘的主要细菌。因此,采用由藜芦醇超分子和虎杖根提取物组成的组合物还可以起到治疗痤疮或祛痘的作用。The inventors further found in the study that the composition obtained by mixing resveratrol supramolecules and Polygonum cuspidatum root extract has an antibacterial effect on Propionibacterium acnes. Since Propionibacterium acnes is the main bacteria that causes acne and pimples, the composition composed of resveratrol supramolecules and Polygonum cuspidatum root extract can also play a role in treating acne or removing pimples.
优选地,白藜芦醇超分子与虎杖根提取物的重量比为1~3:1;Preferably, the weight ratio of resveratrol supramolecule to Polygonum cuspidatum root extract is 1 to 3:1;
最优选地,白藜芦醇超分子与虎杖根提取物的重量比为2:1。Most preferably, the weight ratio of resveratrol supramolecule to Polygonum cuspidatum root extract is 2:1.
优选地,所述的虎杖根提取物通过如下方法制备得到:Preferably, the Polygonum cuspidatum root extract is prepared by the following method:
取虎杖根,用溶剂进行提取,得提取液;将提取液浓缩干燥后得虎杖根溶剂提取物,取虎杖根溶剂提取物即得所述的虎杖根提取物。Take the root of Polygonum cuspidatum, extract it with a solvent to obtain an extract; concentrate and dry the extract to obtain a Polygonum cuspidatum root solvent extract; take the Polygonum cuspidatum root solvent extract to obtain the Polygonum cuspidatum root extract.
优选地,所述的溶剂是由丙酮和甲醇组成的混合溶剂。Preferably, the solvent is a mixed solvent consisting of acetone and methanol.
进一步优选地,丙酮和甲醇的体积比为1:2~4。More preferably, the volume ratio of acetone to methanol is 1:2-4.
最优选地,丙酮和甲醇的体积比为1:3。Most preferably, the volume ratio of acetone to methanol is 1:3.
优选地,虎杖根和溶剂的用量比为1kg:8~20L。Preferably, the usage ratio of Polygonum cuspidatum root to solvent is 1kg:8-20L.
最优选地,虎杖根和溶剂的用量比为1kg:15L。Most preferably, the usage ratio of Polygonum cuspidatum root and solvent is 1kg:15L.
优选地,所述的虎杖根提取物的制备方法,进一步还包含如下步骤:Preferably, the method for preparing the Polygonum cuspidatum root extract further comprises the following steps:
将虎杖根溶剂提取物上大孔树脂柱,先用4~8倍柱体积的体积分数为36~39%的乙醇水溶液洗脱除去杂质;接着再用4~8倍柱体积的体积分数为53~55%的乙醇水溶液洗脱,收集体积分数为53~55%的乙醇水溶液洗脱下来的洗脱液,浓缩干燥后得虎杖根大孔树脂洗脱部位;取虎杖根大孔树脂洗脱部位即得所述的虎杖根提取物。The solvent extract of Polygonum cuspidatum root is placed on a macroporous resin column, and impurities are first eluted with 4 to 8 times the column volume of an ethanol aqueous solution with a volume fraction of 36 to 39%; then it is eluted with 4 to 8 times the column volume of an ethanol aqueous solution with a volume fraction of 53 to 55%, and the eluate eluted with the 53 to 55% ethanol aqueous solution is collected, and after concentrating and drying, the macroporous resin elution portion of Polygonum cuspidatum root is obtained; the Polygonum cuspidatum root extract is obtained by taking the macroporous resin elution portion of Polygonum cuspidatum root.
最优选地,所述的虎杖根提取物的制备方法,进一步还包含如下步骤:Most preferably, the method for preparing the Polygonum cuspidatum root extract further comprises the following steps:
将虎杖根溶剂提取物上大孔树脂柱,先用6倍柱体积的体积分数为38%的乙醇水溶液洗脱除去杂质;接着再用6倍柱体积的体积分数为54%的乙醇水溶液洗脱,收集体积分数为54%的乙醇水溶液洗脱下来的洗脱液,浓缩干燥后得虎杖根大孔树脂洗脱部位;取虎杖根大孔树脂洗脱部位即得所述的虎杖根提取物。The solvent extract of Polygonum cuspidatum root is placed on a macroporous resin column, and impurities are first eluted with 6 times the column volume of 38% ethanol aqueous solution; then it is eluted with 6 times the column volume of 54% ethanol aqueous solution, and the eluate eluted with the 54% ethanol aqueous solution is collected, concentrated and dried to obtain the Polygonum cuspidatum root macroporous resin elution part; the Polygonum cuspidatum root macroporous resin elution part is taken to obtain the Polygonum cuspidatum root extract.
优选地,所述的大孔树脂柱为D101型大孔树脂柱。Preferably, the macroporous resin column is a D101 macroporous resin column.
发明人在研究中发现,将白藜芦醇超分子与进一步通过上述大孔树脂洗脱条件制备得到的虎杖根大孔树脂洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用要显著高于将白藜芦醇超分子与不经大孔树脂洗脱的虎杖根溶剂提取物混合后得到的组合物。The inventors found in their research that the composition obtained by mixing resveratrol supramolecules with the macroporous resin elution part of Polygonum cuspidatum root prepared by the above-mentioned macroporous resin elution conditions has a significantly higher anti-Propionibacterium acnes effect than the composition obtained by mixing resveratrol supramolecules with the solvent extract of Polygonum cuspidatum root without macroporous resin elution.
此外,发明人需要强调的是,本发明的大孔树脂柱洗脱条件十分关键,将白藜芦醇超分子只有与进一步通过本发明所述大孔树脂柱洗脱条件制备得到的虎杖根大孔树脂洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用才能进一步显著高于将白藜芦醇超分子与不经大孔树脂洗脱的虎杖根溶剂提取物混合后得到的组合物;然而,将白藜芦醇超分子与通过其它大孔树脂柱洗脱条件制备得到的虎杖根大孔树脂洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用并不能进一步显著高于将白藜芦醇超分子与不经大孔树脂洗脱的虎杖根溶剂提取物混合后得到的组合物。In addition, the inventors need to emphasize that the elution conditions of the macroporous resin column of the present invention are very critical. Only when the resveratrol supramolecule is mixed with the macroporous resin elution part of the Polygonum cuspidatum root prepared by the macroporous resin column elution conditions of the present invention, the anti-Propionibacterium acnes effect of the composition can be further significantly higher than the composition obtained by mixing the resveratrol supramolecule with the Polygonum cuspidatum root solvent extract without macroporous resin elution; however, the anti-Propionibacterium acnes effect of the composition obtained by mixing the resveratrol supramolecule with the macroporous resin elution part of the Polygonum cuspidatum root prepared by other macroporous resin column elution conditions cannot be further significantly higher than the composition obtained by mixing the resveratrol supramolecule with the Polygonum cuspidatum root solvent extract without macroporous resin elution.
优选地,所述的虎杖根提取物的制备方法,进一步还包含如下步骤:Preferably, the method for preparing the Polygonum cuspidatum root extract further comprises the following steps:
将虎杖根大孔树脂洗脱部位上硅胶柱,先用3~5倍柱体积的体积比为95~98:5~2的氯仿和甲醇组成的混合溶剂洗脱除去杂质;接着再用4~6倍柱体积的体积比为83~85:17~15的氯仿和甲醇组成的混合溶剂洗脱,收集体积的体积比为83~85:17~15的氯仿和甲醇组成的混合溶剂洗脱下来的洗脱液,浓缩干燥后得虎杖根硅胶柱洗脱部位;取虎杖根硅胶柱洗脱部位即得所述的虎杖根提取物。The elution part of the Polygonum cuspidatum root macroporous resin is placed on a silica gel column, and impurities are first eluted with a mixed solvent consisting of chloroform and methanol in a volume ratio of 95-98:5-2 for 3-5 times the column volume; then, it is eluted with a mixed solvent consisting of chloroform and methanol in a volume ratio of 83-85:17-15 for 4-6 times the column volume, and the eluate eluted with the mixed solvent consisting of chloroform and methanol in a volume ratio of 83-85:17-15 is collected, and the elution part of the Polygonum cuspidatum root silica gel column is obtained after concentration and drying; the Polygonum cuspidatum root silica gel column elution part is taken to obtain the Polygonum cuspidatum root extract.
发明人在研究中发现,将白藜芦醇超分子与进一步通过上述硅胶柱洗脱条件制备得到的虎杖根硅胶柱洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用要进一步大幅高于将白藜芦醇超分子与虎杖根大孔树脂洗脱部位混合后得到的组合物。The inventors found in their research that the composition obtained by mixing resveratrol supramolecules with the polygonum cuspidatum root silica gel column elution fraction prepared by the above-mentioned silica gel column elution conditions has a further significantly higher anti-Propionibacterium acnes effect than the composition obtained by mixing resveratrol supramolecules with the polygonum cuspidatum root macroporous resin elution fraction.
同样的,发明人需要强调的是,本发明的硅胶柱洗脱条件十分关键,将白藜芦醇超分子只有与进一步通过本发明所述硅胶柱洗脱条件制备得到的虎杖根硅胶柱洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用才能进一步大幅高于将白藜芦醇超分子与虎杖根大孔树脂洗脱部位混合后得到的组合物;然而,将白藜芦醇超分子与通过其它硅胶柱洗脱条件制备得到的虎杖根硅胶柱洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用并不能进一步大幅高于将白藜芦醇超分子与虎杖根大孔树脂洗脱部位混合后得到的组合物。Similarly, the inventors need to emphasize that the silica gel column elution conditions of the present invention are very critical. Only when the resveratrol supramolecule is mixed with the polygonum cuspidatum root silica gel column elution fraction prepared by the silica gel column elution conditions of the present invention, the anti-Propionibacterium acnes effect of the composition can be further significantly higher than the composition obtained by mixing the resveratrol supramolecule with the polygonum cuspidatum root macroporous resin elution fraction; however, the anti-Propionibacterium acnes effect of the composition obtained by mixing the resveratrol supramolecule with the polygonum cuspidatum root silica gel column elution fraction prepared by other silica gel column elution conditions cannot be further significantly higher than the composition obtained by mixing the resveratrol supramolecule with the polygonum cuspidatum root macroporous resin elution fraction.
优选地,所述的组合物为具有抗痤疮丙酸杆菌作用的组合物。Preferably, the composition is a composition having an anti-Propionibacterium acnes effect.
本发明还提供了一种上述白藜芦醇超分子或组合物在制备具有美白、抗氧化和/或祛痘作用的产品中的应用。The present invention also provides a use of the above-mentioned resveratrol supramolecule or composition in preparing a product with whitening, anti-oxidation and/or acne-removing effects.
优选地,所述的组合物在制备具有抗痤疮丙酸杆菌作用的产品中的应用。Preferably, the composition is used in the preparation of a product having an anti-Propionibacterium acnes effect.
优选地,所述的产品为化妆品或药物。Preferably, the product is a cosmetic or a medicine.
本发明还提供了一种上述白藜芦醇超分子或组合物在制备化妆品中的应用。The present invention also provides an application of the resveratrol supramolecule or composition in the preparation of cosmetics.
优选地,所述的化妆品包括但不限于精华液、乳霜、面膜、洗液、凝胶、喷雾。Preferably, the cosmetics include but are not limited to essences, creams, facial masks, lotions, gels, and sprays.
有益效果:本发明提供了一种全新方法制备得到的白藜芦醇超分子;研究表明,通过本发明所述方法制备得到的白藜芦醇超分子,其相比于等量的白藜芦醇,具有更好的抗氧化作用;此外,相比于白藜芦醇还可以降低对皮肤的刺激。进一步研究表明,将白藜芦醇超分子和虎杖根提取物混合后得到的组合物,其还具有显著甚者优异的抗痤疮丙酸杆菌。因此,将本发明所述的白藜芦醇超分子和/或组合物作为活性成分用于制备化妆品或药物具有重要的应用价值。Beneficial effects: The present invention provides a resveratrol supramolecule prepared by a completely new method; studies have shown that the resveratrol supramolecule prepared by the method of the present invention has a better antioxidant effect than the same amount of resveratrol; in addition, compared with resveratrol, it can also reduce skin irritation. Further studies have shown that the composition obtained by mixing the resveratrol supramolecule and the root extract of Polygonum cuspidatum has significant or even excellent anti-Propionibacterium acnes. Therefore, the resveratrol supramolecule and/or composition of the present invention as an active ingredient for the preparation of cosmetics or drugs has important application value.
附图说明BRIEF DESCRIPTION OF THE DRAWINGS
图1为白藜芦醇纯品核磁共振氢谱。Figure 1 is the H NMR spectrum of pure resveratrol.
图2为本发明白藜芦醇超分子的核磁共振氢谱。FIG. 2 is a hydrogen nuclear magnetic resonance spectrum of the resveratrol supramolecule of the present invention.
图3为羟丙基-β-环糊精纯品核磁共振氢谱。Figure 3 is the H NMR spectrum of pure hydroxypropyl-β-cyclodextrin.
具体实施方式Detailed ways
以下结合具体实施例来进一步解释本发明,但实施例对本发明不做任何形式的限定。The present invention is further explained below in conjunction with specific examples, but the examples do not limit the present invention in any form.
实施例1白藜芦醇超分子的制备Example 1 Preparation of resveratrol supramolecular
取90g羟丙基-β-环糊精加入到270g水中加热至70℃,完全溶清后加入10g白藜芦醇,后在此温度下搅拌2小时,氮气保护下喷雾干燥,进风温度控制在125℃,进样速度保持15ml/min,收集喷雾干燥物即得所述的白藜芦醇超分子。90 g of hydroxypropyl-β-cyclodextrin was added to 270 g of water and heated to 70° C. After it was completely dissolved, 10 g of resveratrol was added, and then stirred at this temperature for 2 hours. The mixture was spray-dried under nitrogen protection, the inlet air temperature was controlled at 125° C., and the injection speed was maintained at 15 ml/min. The spray-dried product was collected to obtain the resveratrol supramolecule.
白藜芦醇:1HNMR(400MHz,CD3OD):δ7.35(d,J=8.4Hz,2H),6.96(d,J=16.4Hz,1H),6.82-6.75(m,3H),6.45-6.44(m,2H),6.16-6.15(m,1H)。谱图见图1。Resveratrol: 1 HNMR (400 MHz, CD 3 OD): δ7.35 (d, J=8.4 Hz, 2H), 6.96 (d, J=16.4 Hz, 1H), 6.82-6.75 (m, 3H), 6.45-6.44 (m, 2H), 6.16-6.15 (m, 1H). See Figure 1 for the spectrum.
白藜芦醇超分子:1HNMR(400MHz,CD3OD):δ7.37(d,J=8.4Hz,2H),6.96(d,J=16.4Hz,1H),6.82-6.76(m,3H)。羟丙基-β-环糊精氢化学位移部分未列出,具体谱图见图2和图3。Resveratrol supramolecular: 1 HNMR (400MHz, CD 3 OD): δ7.37 (d, J=8.4Hz, 2H), 6.96 (d, J=16.4Hz, 1H), 6.82-6.76 (m, 3H). The hydrogen chemical shift of hydroxypropyl-β-cyclodextrin is not listed, and the specific spectra are shown in Figures 2 and 3.
对比白藜芦醇单体和超分子得核磁氢谱,低场区域发生改变,说明白藜芦醇进入羟丙基-β-环糊精内腔,可以确定超分子形成。Comparing the H NMR spectra of resveratrol monomer and supramolecule, changes occurred in the low-field region, indicating that resveratrol entered the inner cavity of hydroxypropyl-β-cyclodextrin, which can confirm the formation of supramolecule.
实验例1人体斑贴实验Experimental Example 1 Human Patch Test
利用白藜芦醇和其按实施例1方法制备得到的白藜芦醇超分子分别配制成膏霜A和B,两者含白藜芦醇浓度相同,其它成分相同,配方组成见表1。表4:膏霜A和B的组成。Resveratrol and the resveratrol supramolecule prepared according to the method of Example 1 were respectively prepared into creams A and B, both of which contained the same concentration of resveratrol and the same other ingredients. The formula compositions are shown in Table 1. Table 4: Compositions of creams A and B.
表1.膏霜重量份组成Table 1. Composition of cream by weight
选择22-49岁的志愿者30名,其中男性9人,女性21人,平均年龄28±6.1岁,符合受试者志愿者入选标准。将膏霜A、B各约0.020-0.025ml加入斑试器内,然后将加有样品的斑试器用无刺激胶带贴敷于受试者的背部,用手掌轻压使之均匀地贴敷于皮肤上,持续24H;去除受试物斑试器,用湿润的脱脂棉球轻轻擦去测试部位的受试物残留,0.5H后,待压痕消失后观察皮肤反应,如结果为阴性,于揭去斑贴24H、48H各再观察一次。按分级标准记录反应结果,如表2所示。30 volunteers aged 22-49 were selected, including 9 males and 21 females, with an average age of 28±6.1 years old, meeting the selection criteria for subject volunteers. About 0.020-0.025 ml of cream A and B were added to the spot tester, and then the spot tester with the sample was applied to the back of the subject with a non-irritating tape, and gently pressed with the palm of the hand to evenly apply it to the skin for 24 hours; the test spot tester was removed, and the test residue on the test site was gently wiped off with a moistened cotton ball. After 0.5 hours, the skin reaction was observed after the indentation disappeared. If the result is negative, it was observed again at 24 hours and 48 hours after the patch was removed. The reaction results were recorded according to the grading standard, as shown in Table 2.
表2.人体斑贴实验Table 2. Human patch test
从表1结果显示白藜芦醇单体配成的膏霜对人体皮肤有一定的刺激,而相同白藜芦醇含量的按实施例1方法制备得到的白藜芦醇超分子配成的膏霜对人体皮肤没有刺激,说明在本发明白藜芦醇超分子中主体分子羟丙基β-环糊精的内腔形成的分子胶囊可以很好的保护客体分子白藜芦醇,减少了白藜芦醇和人体皮肤的直接接触,从而降低了白藜芦醇对人体的刺激。The results in Table 1 show that the cream prepared with resveratrol monomer has certain irritation to human skin, while the cream prepared with resveratrol supramolecule prepared according to the method of Example 1 with the same resveratrol content has no irritation to human skin, indicating that the molecular capsule formed by the inner cavity of the main molecule hydroxypropyl β-cyclodextrin in the resveratrol supramolecule of the present invention can well protect the guest molecule resveratrol, reduce the direct contact between resveratrol and human skin, and thus reduce the irritation of resveratrol to the human body.
实验例2斑马鱼活性测试Experimental Example 2 Zebrafish Activity Test
斑马鱼与人类的基因相似程度高达87%,2003年美国卫生院列为继大鼠小鼠之后的第三大模式生物,有水中“小白鼠”之称。其生理、发育代谢与哺乳类动物高相似,其皮肤结构和人体相似度高,斑马鱼皮肤也有基底层、棘层、颗粒层、透明层和表皮角质细胞层以及人体皮肤结构相同的固有层、板桥粒、黑色素细胞、血管和皮下脂肪细胞等等。因此,斑马鱼可应用于急性有毒物质测试以及功效测试,在化妆品行业已经获得广泛认可。The genetic similarity between zebrafish and humans is as high as 87%. In 2003, the U.S. Institute of Health listed zebrafish as the third largest model organism after rats and mice, and it is known as the "little white mouse" in the water. Its physiology, developmental metabolism are highly similar to those of mammals, and its skin structure is highly similar to that of humans. Zebrafish skin also has a basal layer, spinous layer, granular layer, clear layer and epidermal keratinocyte layer, as well as the same structure of human skin as the lamina propria, basal granules, melanocytes, blood vessels and subcutaneous fat cells, etc. Therefore, zebrafish can be used in acute toxic substance testing and efficacy testing, and has been widely recognized in the cosmetics industry.
斑马鱼体内的ROS调控机制与人体相同,可通过荧光探针2',7'-二氯荧光素二乙酸酯(H2DCFDA)活体染色监测斑马鱼胚胎中的ROS,将其标记为绿色荧光。斑马鱼胚胎个体小,方便于显微镜下拍照,并应用软件分析定量读取斑马鱼胚胎中随着ROS增加而增强的绿色荧光信号,测试比较处理组和空白对照组的鱼胚胎ROS水平变化,计算羟基酪醇清除ROS的能力。The ROS regulation mechanism in zebrafish is the same as that in humans. ROS in zebrafish embryos can be monitored by live staining with the fluorescent probe 2',7'-dichlorofluorescein diacetate (H2DCFDA), which is marked as green fluorescence. Zebrafish embryos are small, which makes it convenient to take pictures under a microscope. Software analysis is used to quantitatively read the green fluorescence signal in zebrafish embryos that increases with the increase of ROS. The changes in ROS levels in fish embryos in the treatment group and the blank control group are tested and compared, and the ability of hydroxytyrosol to remove ROS is calculated.
检测实验的方法是将24尾48小时大斑马鱼胚胎分别暴露于相应白藜芦醇或白藜芦醇超分子溶液中,同时设置空白对照组,暴露24小时后对鱼胚胎进行H2DCFDA染色,荧光拍照测量ROS信号强度并进行统计分析。最终的活性氧(ROS)清除率则按以下公式计算:The method of the detection experiment is to expose 24 48-hour-old zebrafish embryos to the corresponding resveratrol or resveratrol supramolecular solution, and set up a blank control group. After 24 hours of exposure, the fish embryos were stained with H2DCFDA, and the ROS signal intensity was measured by fluorescence photography and statistical analysis. The final reactive oxygen species (ROS) clearance rate was calculated according to the following formula:
清除率=[(C-T)/C]X100%Clearance = [(C-T)/C] X 100%
该式中,T为受试物处理组鱼胚胎ROS“平均信号强度”的平均值;C为空白对照组鱼胚胎ROS“平均信号强度”的平均值,计算结果见表3。In the formula, T is the average value of the “average signal intensity” of ROS in the fish embryos in the test substance treatment group; C is the average value of the “average signal intensity” of ROS in the fish embryos in the blank control group. The calculation results are shown in Table 3.
表3.斑马鱼活性测试Table 3. Zebrafish activity test
从表3实验结果可以看出,白藜芦醇单体在测试浓度为1g/L时对斑马鱼胚胎ROS清除率可以达到90%,效果显著;但测试浓度为0.1g/L、0.005g/L的情况下ROS清除率则降为63%和19%;而白藜芦醇羟丙基β-环糊精超分子在测试浓度为0.5g/L(超分子含白藜芦醇10%,实际白藜芦醇的测试浓度为0.05g/L)时对斑马鱼胚胎ROS清除率就可以高达99%;白藜芦醇超分子的测试浓度为0.25g/L(实际白藜芦醇测试浓度为0.025g/L)时对斑马鱼胚胎ROS清除率仍然可以达到60%。该结果明确显示相同浓度的白藜芦醇,本发明白藜芦醇超分子比白藜芦醇单体具有更好的生物活性,说明超分子主体分子羟丙基β-环糊精形成的分子胶囊不但可以很好的保护客体分子白藜芦醇,而且起到递送、缓释的作用,可以大幅提高客体分子的生物利用度,使相同浓度的客体分子在超分子状态下发挥更好的生物活性,表现出更好的ROS清除率。From the experimental results in Table 3, it can be seen that the ROS scavenging rate of resveratrol monomer on zebrafish embryos can reach 90% when the test concentration is 1g/L, and the effect is significant; but when the test concentrations are 0.1g/L and 0.005g/L, the ROS scavenging rate drops to 63% and 19%; while the ROS scavenging rate of resveratrol hydroxypropyl β-cyclodextrin supramolecular on zebrafish embryos can reach 99% when the test concentration is 0.5g/L (the supramolecular contains 10% resveratrol, and the actual test concentration of resveratrol is 0.05g/L); the ROS scavenging rate of resveratrol supramolecular on zebrafish embryos can still reach 60% when the test concentration of resveratrol supramolecular is 0.25g/L (the actual test concentration of resveratrol is 0.025g/L). The results clearly show that at the same concentration of resveratrol, the resveratrol supramolecular of the present invention has better biological activity than resveratrol monomer, indicating that the molecular capsule formed by the supramolecular host molecule hydroxypropyl β-cyclodextrin can not only well protect the guest molecule resveratrol, but also play a role in delivery and sustained release, which can greatly improve the bioavailability of the guest molecule, so that the guest molecule at the same concentration can exert better biological activity in the supramolecular state and show a better ROS clearance rate.
实施例2组合物的制备Example 2 Preparation of the composition
将按照实施例1方法制备得到的白藜芦醇超分子与虎杖根提取物按2:1的重量比混合均匀后即得到所述的组合物;The resveratrol supramolecule prepared according to the method of Example 1 and the Polygonum cuspidatum root extract are uniformly mixed in a weight ratio of 2:1 to obtain the composition;
所述的虎杖根提取物通过如下方法制备得到:取干燥的虎杖根,用溶剂在56℃下进行回流提取1.5h,得提取液;将提取液浓缩干燥后得虎杖根溶剂提取物;其中,干燥的虎杖根和溶剂的用量比为1kg:15L;所述的溶剂由体积比为1:3的丙酮和甲醇组成;The polygonum cuspidatum root extract is prepared by the following method: taking dried polygonum cuspidatum root, performing reflux extraction with a solvent at 56° C. for 1.5 hours to obtain an extract; concentrating and drying the extract to obtain a polygonum cuspidatum root solvent extract; wherein the amount ratio of dried polygonum cuspidatum root to solvent is 1kg:15L; the solvent is composed of acetone and methanol in a volume ratio of 1:3;
取虎杖根溶剂提取物即得所述的虎杖根提取物。The Polygonum cuspidatum root extract is obtained by taking the Polygonum cuspidatum root solvent extract.
实施例3组合物的制备Example 3 Preparation of the composition
将按照实施例1方法制备得到的白藜芦醇超分子与虎杖根提取物按2:1的重量比混合均匀后即得到所述的组合物;The resveratrol supramolecule prepared according to the method of Example 1 and the Polygonum cuspidatum root extract are uniformly mixed in a weight ratio of 2:1 to obtain the composition;
所述的虎杖根提取物通过如下方法制备得到:The Polygonum cuspidatum root extract is prepared by the following method:
S21.取干燥的虎杖根,用溶剂在56℃下进行回流提取1.5h,得提取液;将提取液浓缩干燥后得虎杖根溶剂提取物;其中,干燥的虎杖根和溶剂的用量比为1kg:15L;所述的溶剂由体积比为1:3的丙酮和甲醇组成;S21. Take dried Polygonum cuspidatum root, reflux extract with solvent at 56°C for 1.5h to obtain an extract; concentrate and dry the extract to obtain a Polygonum cuspidatum root solvent extract; wherein the amount ratio of dried Polygonum cuspidatum root to solvent is 1kg:15L; the solvent is composed of acetone and methanol in a volume ratio of 1:3;
S22.将虎杖根溶剂提取物上大孔树脂柱(大孔树脂柱中填充有虎杖根溶剂提取物重量50倍的D101型大孔树脂),先用6倍柱体积的体积分数为38%的乙醇水溶液洗脱除去杂质;接着再用6倍柱体积的体积分数为54%的乙醇水溶液洗脱,收集体积分数为54%的乙醇水溶液洗脱下来的洗脱液,浓缩干燥后得虎杖根大孔树脂洗脱部位;S22. The root of Polygonum cuspidatum solvent extract was loaded onto a macroporous resin column (the macroporous resin column was filled with 50 times the weight of the root of Polygonum cuspidatum solvent extract of D101 macroporous resin), and impurities were first eluted with 6 times the volume of the column with a volume fraction of 38% ethanol aqueous solution; then eluted with 6 times the volume of the column with a volume fraction of 54% ethanol aqueous solution, and the eluate eluted with a volume fraction of 54% ethanol aqueous solution was collected, and the eluate was concentrated and dried to obtain the root of Polygonum cuspidatum macroporous resin elution part;
取虎杖根大孔树脂洗脱部位即得所述的虎杖根提取物。The Polygonum cuspidatum root extract is obtained by taking the macroporous resin elution part of the Polygonum cuspidatum root.
实施例4组合物的制备Example 4 Preparation of the composition
将按照实施例1方法制备得到的白藜芦醇超分子与虎杖根提取物按2:1的重量比混合均匀后即得到所述的组合物;The resveratrol supramolecule prepared according to the method of Example 1 and the Polygonum cuspidatum root extract are uniformly mixed in a weight ratio of 2:1 to obtain the composition;
所述的虎杖根提取物通过如下方法制备得到:The Polygonum cuspidatum root extract is prepared by the following method:
S21.取干燥的虎杖根,用溶剂在56℃下进行回流提取1.5h,得提取液;将提取液浓缩干燥后得虎杖根溶剂提取物;其中,干燥的虎杖根和溶剂的用量比为1kg:15L;所述的溶剂由体积比为1:3的丙酮和甲醇组成;S21. Take dried Polygonum cuspidatum root, reflux extract with solvent at 56°C for 1.5h to obtain an extract; concentrate and dry the extract to obtain a Polygonum cuspidatum root solvent extract; wherein the amount ratio of dried Polygonum cuspidatum root to solvent is 1kg:15L; the solvent is composed of acetone and methanol in a volume ratio of 1:3;
S22.将虎杖根溶剂提取物上大孔树脂柱(大孔树脂柱中填充有虎杖根溶剂提取物重量50倍的D101型大孔树脂),先用6倍柱体积的体积分数为38%的乙醇水溶液洗脱除去杂质;接着再用6倍柱体积的体积分数为54%的乙醇水溶液洗脱,收集体积分数为54%的乙醇水溶液洗脱下来的洗脱液,浓缩干燥后得虎杖根大孔树脂洗脱部位;S22. The root of Polygonum cuspidatum solvent extract was loaded onto a macroporous resin column (the macroporous resin column was filled with 50 times the weight of the root of Polygonum cuspidatum solvent extract of D101 macroporous resin), and impurities were first eluted with 6 times the volume of the column with a volume fraction of 38% ethanol aqueous solution; then eluted with 6 times the volume of the column with a volume fraction of 54% ethanol aqueous solution, and the eluate eluted with a volume fraction of 54% ethanol aqueous solution was collected, and the eluate was concentrated and dried to obtain the root of Polygonum cuspidatum macroporous resin elution part;
S23.将虎杖根大孔树脂洗脱部位上硅胶柱(硅胶柱中填充有虎杖根大孔树脂洗脱部位重量30倍的200-300目的硅胶),先用4倍柱体积的体积比为96:4的氯仿和甲醇组成的混合溶剂洗脱除去杂质;接着再用5倍柱体积的体积比为84:16的氯仿和甲醇组成的混合溶剂洗脱,收集体积的体积比为84:16的氯仿和甲醇组成的混合溶剂洗脱下来的洗脱液,浓缩干燥后得虎杖根硅胶柱洗脱部位;S23. The elution site of Polygonum cuspidatum macroporous resin was placed on a silica gel column (the silica gel column was filled with 200-300 mesh silica gel 30 times the weight of the elution site of Polygonum cuspidatum macroporous resin), and impurities were removed by elution with a mixed solvent of chloroform and methanol in a volume ratio of 96:4 for 4 times the column volume; then eluted with a mixed solvent of chloroform and methanol in a volume ratio of 84:16 for 5 times the column volume, and the eluate was collected by volume ratio of 84:16 for chloroform and methanol. The eluate was concentrated and dried to obtain the elution site of Polygonum cuspidatum silica gel column;
取虎杖根硅胶柱洗脱部位即得所述的虎杖根提取物。The Polygonum cuspidatum root extract is obtained by taking the elution portion of the Polygonum cuspidatum root silica gel column.
对比例1组合物的制备Comparative Example 1 Preparation of the composition
将按照实施例1方法制备得到的白藜芦醇超分子与虎杖根提取物按2:1的重量比混合均匀后即得到所述的组合物;The resveratrol supramolecule prepared according to the method of Example 1 and the Polygonum cuspidatum root extract are uniformly mixed in a weight ratio of 2:1 to obtain the composition;
所述的虎杖根提取物通过如下方法制备得到:The Polygonum cuspidatum root extract is prepared by the following method:
S21.取干燥的虎杖根,用溶剂在56℃下进行回流提取1.5h,得提取液;将提取液浓缩干燥后得虎杖根溶剂提取物;其中,干燥的虎杖根和溶剂的用量比为1kg:15L;所述的溶剂由体积比为1:3的丙酮和甲醇组成;S21. Take dried Polygonum cuspidatum root, reflux extract with solvent at 56°C for 1.5h to obtain an extract; concentrate and dry the extract to obtain a Polygonum cuspidatum root solvent extract; wherein the amount ratio of dried Polygonum cuspidatum root to solvent is 1kg:15L; the solvent is composed of acetone and methanol in a volume ratio of 1:3;
S22.将虎杖根溶剂提取物上大孔树脂柱(大孔树脂柱中填充有虎杖根溶剂提取物重量50倍的D101型大孔树脂),先用6倍柱体积的体积分数为10%的乙醇水溶液洗脱除去杂质;接着再用6倍柱体积的体积分数为30%的乙醇水溶液洗脱,收集体积分数为30%的乙醇水溶液洗脱下来的洗脱液,浓缩干燥后得虎杖根大孔树脂洗脱部位;S22. The root of Polygonum cuspidatum solvent extract was loaded onto a macroporous resin column (the macroporous resin column was filled with 50 times the weight of the root of Polygonum cuspidatum solvent extract of D101 macroporous resin), and impurities were first eluted with 6 times the volume of the column with a volume fraction of 10% ethanol aqueous solution; then eluted with 6 times the volume of the column with a volume fraction of 30% ethanol aqueous solution, and the eluate eluted with a volume fraction of 30% ethanol aqueous solution was collected, and the eluate was concentrated and dried to obtain the root of Polygonum cuspidatum macroporous resin elution part;
取虎杖根大孔树脂洗脱部位即得所述的虎杖根提取物。The Polygonum cuspidatum root extract is obtained by taking the macroporous resin elution part of the Polygonum cuspidatum root.
对比例1与实施例3的区别在于,大孔树脂柱的洗脱条件不同。The difference between Comparative Example 1 and Example 3 is that the elution conditions of the macroporous resin column are different.
对比例2组合物的制备Comparative Example 2 Preparation of the composition
将按照实施例1方法制备得到的白藜芦醇超分子与虎杖根提取物按2:1的重量比混合均匀后即得到所述的组合物;The resveratrol supramolecule prepared according to the method of Example 1 and the Polygonum cuspidatum root extract are uniformly mixed in a weight ratio of 2:1 to obtain the composition;
所述的虎杖根提取物通过如下方法制备得到:The Polygonum cuspidatum root extract is prepared by the following method:
S21.取干燥的虎杖根,用溶剂在56℃下进行回流提取1.5h,得提取液;将提取液浓缩干燥后得虎杖根溶剂提取物;其中,干燥的虎杖根和溶剂的用量比为1kg:15L;所述的溶剂由体积比为1:3的丙酮和甲醇组成;S21. Take dried Polygonum cuspidatum root, reflux extract with solvent at 56°C for 1.5h to obtain an extract; concentrate and dry the extract to obtain a Polygonum cuspidatum root solvent extract; wherein the amount ratio of dried Polygonum cuspidatum root to solvent is 1kg:15L; the solvent is composed of acetone and methanol in a volume ratio of 1:3;
S22.将虎杖根溶剂提取物上大孔树脂柱(大孔树脂柱中填充有虎杖根溶剂提取物重量50倍的D101型大孔树脂),先用6倍柱体积的体积分数为55%的乙醇水溶液洗脱除去杂质;接着再用6倍柱体积的体积分数为75%的乙醇水溶液洗脱,收集体积分数为75%的乙醇水溶液洗脱下来的洗脱液,浓缩干燥后得虎杖根大孔树脂洗脱部位;S22. The root of Polygonum cuspidatum solvent extract was loaded onto a macroporous resin column (the macroporous resin column was filled with 50 times the weight of the root of Polygonum cuspidatum solvent extract of D101 macroporous resin), and impurities were first eluted with 6 times the volume of the column with a volume fraction of 55% ethanol aqueous solution; then eluted with 6 times the volume of the column with a volume fraction of 75% ethanol aqueous solution, and the eluate eluted with a volume fraction of 75% ethanol aqueous solution was collected, and the eluate was concentrated and dried to obtain the root of Polygonum cuspidatum macroporous resin elution part;
取虎杖根大孔树脂洗脱部位即得所述的虎杖根提取物。The Polygonum cuspidatum root extract is obtained by taking the macroporous resin elution part of the Polygonum cuspidatum root.
对比例2与实施例3的区别在于,大孔树脂柱的洗脱条件不同。The difference between Comparative Example 2 and Example 3 is that the elution conditions of the macroporous resin column are different.
对比例3组合物的制备Comparative Example 3 Preparation of Composition
将按照实施例1方法制备得到的白藜芦醇超分子与虎杖根提取物按2:1的重量比混合均匀后即得到所述的组合物;The resveratrol supramolecule prepared according to the method of Example 1 and the Polygonum cuspidatum root extract are uniformly mixed in a weight ratio of 2:1 to obtain the composition;
所述的虎杖根提取物通过如下方法制备得到:The Polygonum cuspidatum root extract is prepared by the following method:
S21.取干燥的虎杖根,用溶剂在56℃下进行回流提取1.5h,得提取液;将提取液浓缩干燥后得虎杖根溶剂提取物;其中,干燥的虎杖根和溶剂的用量比为1kg:15L;所述的溶剂由体积比为1:3的丙酮和甲醇组成;S21. Take dried Polygonum cuspidatum root, reflux extract with solvent at 56°C for 1.5h to obtain an extract; concentrate and dry the extract to obtain a Polygonum cuspidatum root solvent extract; wherein the amount ratio of dried Polygonum cuspidatum root to solvent is 1kg:15L; the solvent is composed of acetone and methanol in a volume ratio of 1:3;
S22.将虎杖根溶剂提取物上大孔树脂柱(大孔树脂柱中填充有虎杖根溶剂提取物重量50倍的D101型大孔树脂),先用6倍柱体积的体积分数为38%的乙醇水溶液洗脱除去杂质;接着再用6倍柱体积的体积分数为54%的乙醇水溶液洗脱,收集体积分数为54%的乙醇水溶液洗脱下来的洗脱液,浓缩干燥后得虎杖根大孔树脂洗脱部位;S22. The root of Polygonum cuspidatum solvent extract was loaded onto a macroporous resin column (the macroporous resin column was filled with 50 times the weight of the root of Polygonum cuspidatum solvent extract of D101 macroporous resin), and impurities were first eluted with 6 times the volume of the column with a volume fraction of 38% ethanol aqueous solution; then eluted with 6 times the volume of the column with a volume fraction of 54% ethanol aqueous solution, and the eluate eluted with a volume fraction of 54% ethanol aqueous solution was collected, and the eluate was concentrated and dried to obtain the root of Polygonum cuspidatum macroporous resin elution part;
S23.将虎杖根大孔树脂洗脱部位上硅胶柱(硅胶柱中填充有虎杖根大孔树脂洗脱部位重量30倍的200-300目的硅胶),先用4倍柱体积的体积比为99:1的氯仿和甲醇组成的混合溶剂洗脱除去杂质;接着再用5倍柱体积的体积比为90:10的氯仿和甲醇组成的混合溶剂洗脱,收集体积的体积比为90:10的氯仿和甲醇组成的混合溶剂洗脱下来的洗脱液,浓缩干燥后得虎杖根硅胶柱洗脱部位;S23. The elution site of Polygonum cuspidatum macroporous resin was placed on a silica gel column (the silica gel column was filled with 200-300 mesh silica gel 30 times the weight of the elution site of Polygonum cuspidatum macroporous resin), and impurities were removed by elution with a mixed solvent of chloroform and methanol in a volume ratio of 99:1 for 4 times the column volume; then eluted with a mixed solvent of chloroform and methanol in a volume ratio of 90:10 for 5 times the column volume, and the eluate eluted by a mixed solvent of chloroform and methanol in a volume ratio of 90:10 was collected, and the eluate was concentrated and dried to obtain the elution site of Polygonum cuspidatum silica gel column;
取虎杖根硅胶柱洗脱部位即得所述的虎杖根提取物。The Polygonum cuspidatum root extract is obtained by taking the elution portion of the Polygonum cuspidatum root silica gel column.
对比例3与实施例4的区别在于硅胶柱的洗脱条件不同。The difference between Comparative Example 3 and Example 4 is that the elution conditions of the silica gel column are different.
对比例4组合物的制备Preparation of the composition of Comparative Example 4
将按照实施例1方法制备得到的白藜芦醇超分子与虎杖根提取物按2:1的重量比混合均匀后即得到所述的组合物;The resveratrol supramolecule prepared according to the method of Example 1 and the Polygonum cuspidatum root extract are uniformly mixed in a weight ratio of 2:1 to obtain the composition;
所述的虎杖根提取物通过如下方法制备得到:The Polygonum cuspidatum root extract is prepared by the following method:
S21.取干燥的虎杖根,用溶剂在56℃下进行回流提取1.5h,得提取液;将提取液浓缩干燥后得虎杖根溶剂提取物;其中,干燥的虎杖根和溶剂的用量比为1kg:15L;所述的溶剂由体积比为1:3的丙酮和甲醇组成;S21. Take dried Polygonum cuspidatum root, reflux extract with solvent at 56°C for 1.5h to obtain an extract; concentrate and dry the extract to obtain a Polygonum cuspidatum root solvent extract; wherein the amount ratio of dried Polygonum cuspidatum root to solvent is 1kg:15L; the solvent is composed of acetone and methanol in a volume ratio of 1:3;
S22.将虎杖根溶剂提取物上大孔树脂柱(大孔树脂柱中填充有虎杖根溶剂提取物重量50倍的D101型大孔树脂),先用6倍柱体积的体积分数为38%的乙醇水溶液洗脱除去杂质;接着再用6倍柱体积的体积分数为54%的乙醇水溶液洗脱,收集体积分数为54%的乙醇水溶液洗脱下来的洗脱液,浓缩干燥后得虎杖根大孔树脂洗脱部位;S22. The root of Polygonum cuspidatum solvent extract was loaded onto a macroporous resin column (the macroporous resin column was filled with 50 times the weight of the root of Polygonum cuspidatum solvent extract of D101 macroporous resin), and impurities were first eluted with 6 times the volume of the column with a volume fraction of 38% ethanol aqueous solution; then eluted with 6 times the volume of the column with a volume fraction of 54% ethanol aqueous solution, and the eluate eluted with a volume fraction of 54% ethanol aqueous solution was collected, and the eluate was concentrated and dried to obtain the root of Polygonum cuspidatum macroporous resin elution part;
S23.将虎杖根大孔树脂洗脱部位上硅胶柱(硅胶柱中填充有虎杖根大孔树脂洗脱部位重量30倍的200-300目的硅胶),先用4倍柱体积的体积比为85:15的氯仿和甲醇组成的混合溶剂洗脱除去杂质;接着再用5倍柱体积的体积比为70:30的氯仿和甲醇组成的混合溶剂洗脱,收集体积的体积比为70:30的氯仿和甲醇组成的混合溶剂洗脱下来的洗脱液,浓缩干燥后得虎杖根硅胶柱洗脱部位;S23. The elution site of Polygonum cuspidatum macroporous resin was placed on a silica gel column (the silica gel column was filled with 200-300 mesh silica gel 30 times the weight of the elution site of Polygonum cuspidatum macroporous resin), and impurities were removed by elution with a mixed solvent of chloroform and methanol in a volume ratio of 85:15 for 4 times the column volume; then eluted with a mixed solvent of chloroform and methanol in a volume ratio of 70:30 for 5 times the column volume, and the eluate was collected by volume in a mixed solvent of chloroform and methanol in a volume ratio of 70:30, and concentrated and dried to obtain the elution site of Polygonum cuspidatum silica gel column;
取虎杖根硅胶柱洗脱部位即得所述的虎杖根提取物。The Polygonum cuspidatum root extract is obtained by taking the elution portion of the Polygonum cuspidatum root silica gel column.
对比例4与实施例4的区别在于硅胶柱的洗脱条件不同。The difference between Comparative Example 4 and Example 4 is that the elution conditions of the silica gel column are different.
实验例3Experimental Example 3
将待测样品按照倍比稀释法稀释成浓度为256、128、64、32、16、8、4、2、1、0.5、0.25、0.125μg/ml的待测样品溶液;所述的待测样品分别为实施例2~4以及对比例1~4制备得到的组合物。The samples to be tested were diluted into sample solutions with concentrations of 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, and 0.125 μg/ml according to the doubling dilution method; the samples to be tested were the compositions prepared in Examples 2 to 4 and Comparative Examples 1 to 4, respectively.
将浓度为1×107cfu/ml的痤疮丙酸杆菌菌液加入到在96孔板中,实验组中依次加入上述浓度的待测样品溶液;接着将96孔板放入细胞培养箱中,在37℃的温度下培养24h;另外,设置不加待测样品溶液的空白对照组;每组设置3个复孔。A 1×10 7 cfu/ml Propionibacterium acnes bacterial solution was added to a 96-well plate, and the test sample solutions of the above concentrations were added to the experimental groups in sequence; then the 96-well plate was placed in a cell culture incubator and cultured at 37°C for 24 hours; in addition, a blank control group without the test sample solution was set up; 3 replicate wells were set up for each group.
培养结束后,用酶标仪检测每孔内在600nm下吸光度值A,根据吸光度值A计算每组每个待测样品浓度条件下细胞的抑制率;抑制率=(1-A测试组/A空白对照组)×100%,进一步用SPSS统计软件计算IC50值;结果见表4。After the culture was completed, the absorbance value A at 600 nm in each well was detected by an ELISA instrument, and the inhibition rate of the cells under each test sample concentration condition in each group was calculated according to the absorbance value A; inhibition rate = (1-A test group /A blank control group ) × 100%, and the IC 50 value was further calculated using SPSS statistical software; the results are shown in Table 4.
表4.本发明组合物抗痤疮丙酸杆菌实验结果Table 4. Experimental results of the composition of the present invention against Propionibacterium acnes
从表4实验结果可以看出,实施例2制备得到的组合物,其抗痤疮丙酸杆菌的IC50值为25.3μg/ml;这说明:将白藜芦醇超分子和虎杖根提取物(虎杖根溶剂提取物)混合后得到的组合物,其对痤疮丙酸杆菌具有抗菌效果。From the experimental results in Table 4, it can be seen that the IC 50 value of the composition prepared in Example 2 against Propionibacterium acnes is 25.3 μg/ml; this shows that the composition obtained by mixing resveratrol supramolecules and Polygonum cuspidatum root extract (Polygonum cuspidatum root solvent extract) has an antibacterial effect on Propionibacterium acnes.
从表4实验结果可以看出,实施例3制备得到的组合物,其抗痤疮丙酸杆菌的IC50值要显著低于实施例2;这说明:将白藜芦醇超分子与进一步通过本发明大孔树脂洗脱条件制备得到的虎杖根大孔树脂洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用要显著高于将白藜芦醇超分子与不经大孔树脂洗脱的虎杖根溶剂提取物混合后得到的组合物。It can be seen from the experimental results in Table 4 that the IC 50 value of the composition prepared in Example 3 against Propionibacterium acnes is significantly lower than that in Example 2; this indicates that the composition obtained by mixing the resveratrol supramolecule with the Polygonum cuspidatum root macroporous resin elution fraction prepared by the macroporous resin elution conditions of the present invention has a significantly higher anti-Propionibacterium acnes effect than the composition obtained by mixing the resveratrol supramolecule with the Polygonum cuspidatum root solvent extract not eluted with the macroporous resin.
从表4实验结果可以看出,对比例1制备得到的组合物,其抗痤疮丙酸杆菌的IC50值与实施例2相比,虽然有降低,但是降低得不显著;对比例2制备得到的组合物,其抗痤疮丙酸杆菌的IC50值与实施例2相比,反而大幅升高了。这说明:本发明的大孔树脂柱洗脱条件十分关键,不同大孔树脂洗脱条件洗脱得到的虎杖根大孔树脂洗脱部位,其中的有效成分的种类和含量是完全不同的;这就导致了其抗痤疮丙酸杆菌的作用大小也是完全不同的;上述实验结果表明,将白藜芦醇超分子只有与进一步通过本发明所述大孔树脂柱洗脱条件制备得到的虎杖根大孔树脂洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用才能进一步显著高于将白藜芦醇超分子与不经大孔树脂洗脱的虎杖根溶剂提取物混合后得到的组合物;然而,将白藜芦醇超分子与通过其它大孔树脂柱洗脱条件制备得到的虎杖根大孔树脂洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用并不能进一步显著高于将白藜芦醇超分子与不经大孔树脂洗脱的虎杖根溶剂提取物混合后得到的组合物。It can be seen from the experimental results in Table 4 that the IC 50 value of the composition prepared in Comparative Example 1 against Propionibacterium acnes is lower than that in Example 2, but the reduction is not significant; the IC 50 value of the composition prepared in Comparative Example 2 against Propionibacterium acnes is significantly increased compared with that in Example 2. This shows that: the elution conditions of the macroporous resin column of the present invention are very critical, and the types and contents of the effective ingredients in the macroporous resin elution parts of the Polygonum cuspidatum root obtained by eluting with different macroporous resin elution conditions are completely different; this leads to completely different effects against Propionibacterium acnes; the above experimental results show that only when the resveratrol supramolecule is mixed with the macroporous resin elution part of the Polygonum cuspidatum root prepared by the macroporous resin column elution conditions of the present invention, the anti-Propionibacterium acnes effect of the composition can be further significantly higher than that of the composition obtained by mixing the resveratrol supramolecule with the Polygonum cuspidatum root solvent extract without macroporous resin elution; however, the anti-Propionibacterium acnes effect of the composition obtained by mixing the resveratrol supramolecule with the macroporous resin elution part of the Polygonum cuspidatum root prepared by other macroporous resin column elution conditions cannot be further significantly higher than that of the composition obtained by mixing the resveratrol supramolecule with the Polygonum cuspidatum root solvent extract without macroporous resin elution.
从表4实验结果可以看出,实施例4制备得到的组合物,其抗痤疮丙酸杆菌的IC50值要进一步大幅低于实施例3;这说明:将白藜芦醇超分子与进一步通过本发明硅胶柱洗脱条件制备得到的虎杖根硅胶柱洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用要进一步大幅高于将白藜芦醇超分子与虎杖根大孔树脂洗脱部位混合后得到的组合物。It can be seen from the experimental results in Table 4 that the IC 50 value of the composition prepared in Example 4 against Propionibacterium acnes is further significantly lower than that in Example 3; this indicates that the composition obtained by mixing the resveratrol supramolecule with the polygonum cuspidatum root silica gel column elution fraction prepared by the silica gel column elution conditions of the present invention has an anti-Propionibacterium acnes effect that is further significantly higher than the composition obtained by mixing the resveratrol supramolecule with the polygonum cuspidatum root macroporous resin elution fraction.
从表1实验结果可以看出,对比例3制备得到的组合物,其抗痤疮丙酸杆菌的IC50值与实施例3相比,虽然有降低,但是降低得不显著;对比例4制备得到的组合物,其抗痤疮丙酸杆菌的IC50值与实施例3相比,不但没有降低反而升高了。这说明:本发明的硅胶柱洗脱条件十分关键,不同硅胶柱洗脱条件洗脱得到的虎杖根硅胶柱洗脱部位,其中的有效成分的种类和含量是完全不同的;这就导致了其抗痤疮丙酸杆菌的作用大小也是完全不同的;上述实验结果表明,将白藜芦醇超分子只有与进一步通过本发明所述硅胶柱洗脱条件制备得到的虎杖根硅胶柱洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用才能进一步大幅高于将白藜芦醇超分子与虎杖根大孔树脂洗脱部位混合后得到的组合物;然而,将白藜芦醇超分子与通过其它硅胶柱洗脱条件制备得到的虎杖根硅胶柱洗脱部位混合后得到的组合物,其抗痤疮丙酸杆菌的作用并不能进一步大幅高于将白藜芦醇超分子与虎杖根大孔树脂洗脱部位混合后得到的组合物。It can be seen from the experimental results in Table 1 that the IC 50 value of the composition prepared in Comparative Example 3 against Propionibacterium acnes is lower than that in Example 3, but the reduction is not significant; the IC 50 value of the composition prepared in Comparative Example 4 against Propionibacterium acnes is not lowered but increased compared with that in Example 3. This shows that: the silica gel column elution conditions of the present invention are very critical, and the types and contents of the effective ingredients in the polygonum cuspidatum root silica gel column elution parts obtained by eluting with different silica gel column elution conditions are completely different; this leads to completely different effects against Propionibacterium acnes; the above experimental results show that only when the resveratrol supramolecule is mixed with the polygonum cuspidatum root silica gel column elution part prepared by the silica gel column elution conditions of the present invention, the anti-Propionibacterium acnes effect of the composition can be further significantly higher than that of the composition obtained by mixing the resveratrol supramolecule with the polygonum cuspidatum root macroporous resin elution part; however, the anti-Propionibacterium acnes effect of the composition obtained by mixing the resveratrol supramolecule with the polygonum cuspidatum root silica gel column elution part prepared by other silica gel column elution conditions cannot be further significantly higher than that of the composition obtained by mixing the resveratrol supramolecule with the polygonum cuspidatum root macroporous resin elution part.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410555518.5A CN118436556B (en) | 2024-05-07 | 2024-05-07 | A resveratrol supramolecule and its preparation method and application in preparing cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410555518.5A CN118436556B (en) | 2024-05-07 | 2024-05-07 | A resveratrol supramolecule and its preparation method and application in preparing cosmetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118436556A true CN118436556A (en) | 2024-08-06 |
| CN118436556B CN118436556B (en) | 2025-01-28 |
Family
ID=92329666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410555518.5A Active CN118436556B (en) | 2024-05-07 | 2024-05-07 | A resveratrol supramolecule and its preparation method and application in preparing cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118436556B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277954A (en) * | 2000-07-20 | 2000-12-27 | 北京市孚曼生物技术研究所 | Method for separating reseveratrol from resveratrol glucoside and application thereof |
| JP2006052146A (en) * | 2004-08-10 | 2006-02-23 | Ichimaru Pharcos Co Ltd | Beautifully whitening agent |
| US20090011056A1 (en) * | 2007-07-04 | 2009-01-08 | Qiaojie Cheng | Lingonberry extract, methods of preparing, and uses thereof |
| US20180273514A1 (en) * | 2017-03-22 | 2018-09-27 | Hangzhou Normal University | Series of Resveratrol-Derivative Fluorescently Labeled Molecules and Synthesis Method Thereof |
| CN109988203A (en) * | 2017-12-31 | 2019-07-09 | 中国医学科学院药物研究所 | Polygoside crystal IV substance and preparation method and pharmaceutical composition and use thereof |
-
2024
- 2024-05-07 CN CN202410555518.5A patent/CN118436556B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1277954A (en) * | 2000-07-20 | 2000-12-27 | 北京市孚曼生物技术研究所 | Method for separating reseveratrol from resveratrol glucoside and application thereof |
| JP2006052146A (en) * | 2004-08-10 | 2006-02-23 | Ichimaru Pharcos Co Ltd | Beautifully whitening agent |
| US20090011056A1 (en) * | 2007-07-04 | 2009-01-08 | Qiaojie Cheng | Lingonberry extract, methods of preparing, and uses thereof |
| US20180273514A1 (en) * | 2017-03-22 | 2018-09-27 | Hangzhou Normal University | Series of Resveratrol-Derivative Fluorescently Labeled Molecules and Synthesis Method Thereof |
| CN109988203A (en) * | 2017-12-31 | 2019-07-09 | 中国医学科学院药物研究所 | Polygoside crystal IV substance and preparation method and pharmaceutical composition and use thereof |
Non-Patent Citations (6)
| Title |
|---|
| PATEICIA.FARRIS: "《药妆品与美容实践》", vol. 1, 31 October 2020, 河南科学技术出版社, pages: 166 * |
| 刘树兴, 程丽英, 杨大庆: "虎杖中白藜芦醇与大黄素的综合提取", 天然产物研究与开发, no. 05, 30 October 2005 (2005-10-30) * |
| 李晨等: "白藜芦醇环糊精包合物制备与性能", 《江西科学》, vol. 38, no. 6, 31 December 2020 (2020-12-31), pages 6 - 8 * |
| 程丽英等: "大孔吸附树脂法与高速逆流色谱法分离纯化虎杖中白藜芦醇的比较研究", 《中州大学学报》, vol. 34, no. 4, 31 August 2017 (2017-08-31), pages 1 - 3 * |
| 郑可利;郑小林;吴青青;: "超声波辅助提取虎杖中白藜芦醇工艺研究", 宝鸡文理学院学报(自然科学版), no. 02, 15 June 2008 (2008-06-15) * |
| 陈琼玲等: "大孔树脂-硅胶柱层析法纯化花生根中白藜芦醇", 《中国食品学报》, vol. 14, no. 6, 30 June 2014 (2014-06-30), pages 127 - 132 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118436556B (en) | 2025-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6158219B2 (en) | Composition for treating skin pigmentation | |
| CN107334726A (en) | A kind of acne-removing composition and its preparation method and application | |
| DE102009012270A1 (en) | Brassocattleya Marcella Koss Orchid extract and its use as a skin depigmenting agent | |
| JP2017502087A (en) | A plant extract containing, as an active ingredient, a sucrose ester used in a cosmetic composition, dermatological composition, or nutritional cosmetic composition | |
| CN116570525B (en) | Composition with soothing effect, preparation method and use thereof | |
| JP3533737B2 (en) | Bioaging agent and skin composition | |
| WO2012014901A1 (en) | Carbonylation inhibitor | |
| JP5101769B2 (en) | Antibiotic antioxidant or preventive agent | |
| Song et al. | Lactobacillus plantarum fermented Laminaria japonica alleviates UVB-induced epidermal photoinflammation via the Keap-1/Nrf2 pathway | |
| JPH06336421A (en) | External agent for skin | |
| JP2003012532A (en) | Hyaluronidase inhibitor, hexosaminidase liberation inhibitor, cyclic amp phosphodiesterase inhibitor and cosmetic for ameliorating skin roughening | |
| CN118436556A (en) | A resveratrol supramolecule and its preparation method and application in the preparation of cosmetics | |
| JP2002249438A (en) | Age retardant for living organism | |
| KR101698410B1 (en) | Composition for improving skin conditions and preventing or treating proliferative skin diseases containing fermented extracts of sedum as active ingredient | |
| JP2005263655A (en) | Antioxidant | |
| CN110755310B (en) | Active composition for promoting skin microcirculation and preparation method and application thereof | |
| CN116217754A (en) | 4-alkyl resorcinol cyclodextrin derivative supermolecule, preparation method thereof and application thereof in preparing cosmetics | |
| CN109010094A (en) | A kind of resveratrol beautifying face and moistering lotion cosmetics and preparation method | |
| CN116376042B (en) | Preparation method of EUK-134 supermolecule, EUK-134 supermolecule obtained by preparation method and application of EUK-134 supermolecule | |
| JP5991877B2 (en) | Cosmetics containing young leaf extract | |
| CN115700114A (en) | Anti-aging composition, application thereof and eye cream containing composition | |
| JP2021113172A (en) | Peptidyl arginine deiminase 1 expression promoter | |
| KR102775224B1 (en) | Method for producing lactoferrin derivative having functions such as antioxidant, whitening, anti-inflammatory and skin protection, and skin treatment ointment and cosmetic composition comprising the same | |
| KR102676799B1 (en) | External Composition Comprising Natural Complex Extract for Improving Skin | |
| CN116422002B (en) | Aloe extract and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |